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Prostate cancer
Prostate cancer constitutes a major health burden, being 
the  most  common  non-cutaneous  malignancy  among 
men in developed countries. In 2007, almost 800,000 new 
cases  of  prostate  cancer  and  250,000  deaths  from  this 
disease were estimated to have occurred worldwide [1]. 
The highest incidence of prostate cancer is observed in 
the  USA,  with  192,280  new  cases  and  27,360  deaths 
expected in 2009, thereby being the second most common 
cause  of  cancer-related  death  [2].  Prostate  cancer  is  a 
heterogeneous  disease  and  its  natural  history  is  not 
completely understood. Early autopsy studies have shown 
a high prevalence of clinically undetected prostate cancer 
at time of death. In the USA, more than one in three men 
over 50 years of age had histologic evidence of prostate 
cancer at autopsy and this prevalence was observed to 
increase with age, with more than 67% of men aged over 
80  years  having  prostate  cancer  at  time  of  death  [3]. 
These findings indicate that a high proportion of prostate 
tumors are clinically insignificant and will never lead to a 
lethal  outcome.  Furthermore,  the  introduction  and 
widespread application of prostate-specific antigen (PSA) 
testing has led to increased detection of early-stage, low-
volume,  non-palpable  tumors.  This  has  in  turn  raised 
concerns  of  increased  overdiagnosis  and  unnecessary 
treatment  of  indolent  disease  [4,5].  To  this  end,  new 
strategies  to  help  clinicians  distinguish  between  lethal 
and  indolent  prostate  cancer  are  urgently  needed. 
Prostate cancer is one of the most heritable cancers in 
men and recent studies have revealed numerous genetic 
variants associated with this disease. This review will give 
an overview of the current knowledge of prostate cancer 
genetics,  with  a  special  focus  on  the  ability  of  genetic 
variants to predict more aggressive forms.
Prostate cancer susceptibility variants
A family history of prostate cancer is one of the strongest 
risk factors, and twin studies suggest that as much as 42% 
of the disease risk is explained by heritable factors [6]. 
Attempts  to  decipher  the  heritable  component  of 
prostate  cancer  based  on  candidate  gene  association 
studies and genome-wide linkage studies in multiple case 
families have suggested numerous prostate cancer sus-
cep  tibility genes and loci. However, an inability to repli-
cate  reported  linkage  and  association  findings  suggest 
that prostate cancer is genetically complex with multiple 
common  low-penetrance  genes  involved  in  prostate 
cancer predisposition [7]. Recently, genome-wide asso-
cia  tion  studies  (GWAS)  have  emerged  as  a  powerful 
method  to  identify  genomic  low-risk  susceptibility 
regions  for  complex  diseases,  including  cancer  [8]. 
Through genotyping platforms that explore hundreds of 
thousands  of  single  nucleotide  polymorphisms  (SNPs) 
simultaneously,  it  is  possible  to  screen  the  complete 
genome  for  common  genetic  variation  associated  with 
the disease of interest. In 2006 the first prostate cancer 
susceptibility region was identified at chromosome 8q24. 
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analysis  in  Icelandic  families  with  prostate  cancer, 
followed up by association analysis in three independent 
case-control  populations  [9],  and  separately  through 
admixture mapping in African Americans [10]. Subse-
quent GWAS and region-focused studies have revealed 
five  distinct  linkage  disequilibrium  blocks  harboring 
prostate cancer susceptibility alleles at 8q24 [11-17]. The 
8q24 region has also been shown to harbor susceptibility 
alleles  for  breast  cancer  [18],  colorectal  cancer  [19], 
bladder cancer [20], and ovarian cancer [14]. The 1.2 Mb 
sequence  at  8q24  containing  all  observed  risk  alleles 
does  not  code  for  any  known  genes,  and  the  biologic 
mecha  nisms underlying these associations are unknown. 
The  oncogene  c-Myc  is  the  closest  distal  gene  to  this 
region  and  it  has  been  suggested  that  the  observed 
associations  reflect  long-range  control  of  Myc 
expression;  however,  further  functional  studies  are 
needed  to  reveal  the  role  that  these  variants  play  in 
cancer  susceptibility.  To  date,  29  distinct  genetic  loci 
harboring  prostate  cancer  risk  alleles  have  been 
identified  and  consistently  repli  cated  (Table  1).  In 
general, the effect of variants in these regions on prostate 
cancer risk is modest, with odds ratios typically ranging 
between  1.1  and  1.3.  It  has  been  esti  mated  [21]  that 
hitherto  identified  variants  together  explain 
approximately 22% of the familial risk of prostate cancer, 
and  it  is  anticipated  that  many  more  prostate  cancer 
susceptibility variants will be identified in the future.
Prostate cancer susceptibility variants and disease 
aggressiveness
To date there is no reliable way of predicting whether 
prostate  cancer  will  be  an  aggressive,  fast-growing 
disease or a non-aggressive, slow-growing type of cancer. 
In general, a combination of tumor staging (using the 
tumor,  node,  metastasis  staging  system  [22]),  tumor 
grading  (using  the  Gleason  scoring  system  [23])  and 
diagnostic PSA serum levels are used to classify patients 
into differ  ent prognostic risk groups to guide clinicians 
in  treat  ment  decisions.  In  genetic  association  studies, 
patients with prostate cancer are commonly classified as 
having  a  more  aggressive  form  of  the  disease  if  they 
fulfill  any  of  the  following  criteria:  (1)  disease  spread 
outside of the prostate gland, or presence of cancer in 
the lymph nodes or other metastatic sites; (2) presence 
of  poorly  differ  en  tiated  cancer  as  indicated  by  a  high 
Gleason score (that is, 4 + 3 = 7 or higher); or (3) a serum 
PSA level associated with a high likelihood of extensive 
disease (that is, >20 ng/ml).
Several  studies  have  explored  the  capacity  of  estab-
lished prostate cancer risk variants to distinguish between 
less aggressive and more aggressive disease [9-13,24-46]. 
Overall,  results  are  inconclusive,  with  some  studies 
reporting stronger associations for some of these variants 
among  patients  with  more  aggressive  prostate  cancer, 
while others did not. In a large replication study from the 
PRACTICAL  (Prostate  Cancer  Association  Group  to 
Investigate Cancer Associated Alterations in the Genome) 
consortium, which evaluated genetic variants at chromo-
some 3p12, 6q25, 7q21, 10q11, 11q13, 19q13 and Xp11 
among 7,370 prostate cancer cases and 5,742 controls, no 
association with tumor grade was observed for any of the 
explored variants [45]. Fitzgerald and coworkers assessed 
the same seven variants and an additional six variants at 
chromosome  7p15,  8q24,  10q26,  and  17q12  in  a 
population-based study comprising 1,308 cases and 1,267 
controls for association with family history and clinical 
features of more aggressive disease [46]. No association 
was observed between any of the evaluated risk variants 
and  a  composite  measure  of  disease  aggressiveness; 
however, two variants, rs10993994 at 10q11 (P = 0.02) 
and rs5945619 at Xp11 (P = 0.03), were nominally signifi-
cantly associated with Gleason score. 
Most of the published studies exploring established risk 
variants  with  respect  to  prostate  cancer  aggressiveness 
have had several limitations, including small sample size, 
heterogeneous  definition  of  aggressive  disease  across 
multiple  study  populations,  and  reliance  on  clinical 
grading and staging of tumors. To address these limita-
tions, Kader and coworkers evaluated 20 established risk 
variants  in  17  distinct  genomic  regions  among  5,895 
patients  with  prostate  cancer  who  were  of  European 
descent  and  who  underwent  radical  prostatectomy  for 
treatment  of  prostate  cancer  [47].  Based  on  the  entire 
prostate  gland,  each  tumor  was  uniformly  graded  and 
staged using the same protocol. Tumors with pathologic 
Gleason scores of 4+3 or higher, or pathologic stage of 
T3b  or  higher,  or  non-organ  confined  disease,  were 
defined as more aggressive disease (N = 1,253); tumors 
with organ confined disease, pathologic Gleason score of 
3+4 or lower, and pathologic stage of T2 were classified 
as less aggressive disease (N = 4,233). For 18 of the 20 
variants explored, no significant difference was observed 
in  risk  allele  frequencies  between  patients  with  more 
aggressive and less aggressive disease. Two variants were 
significantly associated with disease aggressiveness: SNP 
rs2735839 downstream of the kallikrein 3 gene (KLK3; 
P = 8.4 × 10-7), which is the gene coding for PSA; and SNP 
rs10993994 in the microseminoprotein β gene (MSMB; 
P = 0.046). To reduce the possible impact of heterogeneity 
in the definition of aggressive disease, risk variants were 
also  tested  for  association  with  Gleason  score  and 
pathological stage separately. SNP rs2735839 in the KLK3 
gene (P = 7.7 × 10-6) and SNP rs10993994 in the MSMB 
gene (P = 0.02) were the only variants associated with 
Gleason score. For tumor stage, only SNP rs2735839 in 
the KLK3 gene was significant (P = 1.9 × 10-4). Of note, 
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with  increased  risk  for  prostate  cancer  were  more 
frequent in patients with less aggressive disease. Since 
these risk alleles have been shown to strongly associate 
with  higher  PSA  levels  among  population  controls 
[28,48,49],  it  is  possible  that  the  observed  association 
with  aggressive  disease  may  partly  reflect  a  PSA 
detection bias. 
Table 1. Established prostate cancer susceptibility alleles
dbSNP number  Chromosome  Genea  Risk alleleb  Study
rs1465618  2p21  THADA  A  Eeles et al. 2009 [21] 
rs721048  2p15  EHBP1  A  Gudmundsson et al. 2008 [27] 
rs12621278  2q31.1  ITGA6  A  Eeles et al. 2009 [21] 
rs4857841  3q21.3  EEFSEC  A  Gudmundsson et al. 2009 [57] 
rs12500426  4q22.3  PDLIM5  A  Eeles et al. 2009 [21] 
rs17021918  4q22.3  PDLIM5  C  Eeles et al. 2009 [21] 
rs7679673  4q24  FLJ20032  C  Eeles et al. 2009 [21] 
rs9364554  6q25.3  SLC22A3  T  Eeles et al. 2008 [28] 
rs10486567  7p15.2  JAZF1  G  Thomas et al. 2008 [26] 
rs6465657  7q21.3  LMTK2  C  Eeles et al. 2008 [28] 
rs1512268  8p21.2  NKX3-1  T  Eeles et al. 2009 [21] 
rs12543663  8q24.21    C  Al Olama et al. 2009 [16] 
rs10086908  8q24.21    T  Al Olama et al. 2009 [16] 
rs1016343  8q24.21    T  Al Olama et al. 2009 [16]
rs13252298  8q24.21    A  Al Olama et al. 2009 [16]
rs6983561  8q24.21    C  Al Olama et al. 2009 [16]
rs16901979  8q24.21    A  Gudmundsson et al. 2007 [11]
rs16902094  8q24.21    G  Gudmundsson et al. 2009 [57] 
rs445114  8q24.21    T  Gudmundsson et al. 2009 [57] 
rs620861  8q24.21    C  Al Olama et al. 2009 [16] 
rs6983267  8q24.21    G  Al Olama et al. 2009 [16] 
rs1447295  8q24.21    A  Amundadottir et al. 2006 [9] 
rs10993994  10q11.23  MSMB  T  Eeles et al. 2008 [28] 
rs4962416  10q26.13  CTBP2  C  Thomas et al. 2008 [26] 
rs7127900  11p15.5    A  Eeles et al. 2009 [21] 
rs12418451  11q13.2    A  Zheng et al. 2009 [34]
rs11228565  11q13.2    A  Gudmundsson et al. 2009 [57] 
rs10896449  11q13.2    G  Thomas et al. 2008 [26] 
rs11649743  17q12  HNF1B  G  Sun et al. 2008 [30] 
rs4430796  17q12  HNF1B  A  Gudmundsson et al. 2007 [11] 
rs1859962  17q24.3    G  Gudmundsson et al. 2007 [11] 
rs8102476  19q13.2  PPP1R14A  C  Gudmundsson et al. 2009 [57] 
rs2735839  19q13.33  KLK3  A  Eeles et al. 2008 [28] 
rs9623117  22q13.1  TNRC6B  C  Sun et al. 2009 [31] 
rs5759167  22q13.2  BIK  G  Eeles et al. 2009 [21] 
rs5945619  Xp11.22  NUDT11  C  Eeles et al. 2008 [28] 
aGenes within the linkage-disequilibrium block defined by the associated variant: BIK, BCL2-interacting killer; CTBP2, C-terminal binding protein 2 isoform 2; 
EEFSEC, elongation factor for selenoprotein translation; EHBP1, EH domain binding protein 1; FLJ20032, hypothetical protein LOC54790; HNF1B, hepatocyte nuclear 
factor 1 homeobox B; ITGA6, integrin alpha chain 6; JAZF1, juxtaposed with another zinc finger gene 1; KLK3, kallikrein 3; LMTK2, lemur tyrosine kinase 2; MSMB, 
β-microseminoprotein isoform a precursor; NKX3-1, NK3 transcription factor related locus 1; NUDT11, nudix-type motif 11; PDLIM5, PDZ and LIM domain 5 isoform 
d; PPP1R14A, protein phosphatase 1 regulatory inhibitor; SLC22A3, solute carrier family 22 member 3; SLC25A37, mitochondrial solute carrier protein; THADA, thyroid 
adenoma associated isoform 1; TNRC6B, trinucleotide repeat containing 6B isoform 2. bRisk alleles as defined from published data cited in the column.
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established  prostate  cancer  risk  variants  and  disease 
aggressiveness  does  not  imply  non-existence  of  such 
genetic variants in the genome. All susceptibility variants 
identified  to  date  were  discovered  using  case-control 
designs comparing unaffected individuals with all types 
of patients with prostate cancer. It has been argued that a 
more  effective  design  to  identify  genetic  variants 
associated with aggressive disease should involve a case-
case  design  contrasting  patients  with  more  and  less 
aggressive  disease.  Support  for  this  idea  was  recently 
provided in a study including 4,829 patients with more 
aggressive disease and 12,205 patients with less aggressive 
disease  from  seven  study  populations  [50].  Initially, 
publicly available genotype data for approximately 27,000 
genetic  variants  across  the  genome  were  explored  for 
association  with  disease  severity  among  patients  with 
prostate cancer from four populations examined in the 
Cancer Genetic Markers of Susceptibility study using a 
case-case design. A subset of variants (n = 74), showing 
association  within  each  Cancer  Genetic  Markers  of 
Susceptibility  study,  and  where  the  direction  of  asso-
ciation  was  consistent  among  all  four  studies,  was 
selected  for  further  evaluation  in  an  additional  three 
study  populations  from  Sweden  and  the  USA.  This 
revealed  one  genetic  variant  (rs4054823  at  17p12)  for 
which the TT genotype was consistently higher among 
patients  with  more  aggressive  compared  with  less 
aggressive  disease  in  each  of  the  seven  populations 
studied (overall P = 2.1 × 10-8 under a recessive genetic 
model). If confirmed in independent study populations, 
this  finding  is  of  great  importance,  not  because  of 
immediate clinical utility, but as a proof of principle that 
genetic variants predisposing to more aggressive prostate 
cancer exist. 
Prostate cancer susceptibility variants and disease 
progression and prognosis
In contrast to exploring inherited genetic variants asso-
ciated with aggressiveness of disease at time of diagnosis, 
only  a  few  studies  have  assessed  the  importance  of 
established risk variants on prostate cancer progression 
and prognosis. 
Only one study has explored confirmed risk variants in 
relation  to  prostate  cancer  progression.  Among  320 
patients  who  were  recruited  from  three  hospitals  in 
Taiwan where they were treated with radical prosta  tec-
tomy,  Huang  and  co-workers  explored  association 
between 20 prostate cancer risk variants and biochemical 
failure defined by recurrence of PSA [51]. During a mean 
follow-up of 38.5 months, biochemical failure occurred 
in 113 (35%) of the patients. In univariate analysis, three 
risk  variants  (rs1447295  at  8q24,  and  rs7920517  and 
rs10993994  at  10q11)  were  associated  with  PSA 
recurrence.  Interestingly,  these  associations  remained 
signi  ficant  after  adjusting  for  established  prognostic 
factors such as age, preoperative PSA level, tumor stage, 
Gleason score, and surgical margin, suggesting that these 
variants  may  improve  prediction  of  PSA  recurrence 
among  patients  treated  with  radical  prostatectomy. 
Further studies are required to validate these findings.
Penney  and  co-workers  [52]  explored  eight  genetic 
variants  at  chromosome  8q24,  17q12,  and  17q24.3  for 
association  with  prostate  cancer  mortality  in  three  US 
prostate cancer study populations comprising a total of 
6,460 patients of which 493 died as a result of prostate 
cancer during follow-up. None of the explored variants 
was associated with prostate cancer mortality, neither in 
analysis contrasting lethal cases with long-time survivors 
(alive over 10 years after diagnosis), nor in survival analysis 
among all patients. The total number of risk alleles was 
also not associated with prostate cancer mortality.
A prospective population-based cohort study of Swedish 
patients  with  prostate  cancer  explored  the  association 
between 16 established risk variants and prostate cancer 
mortality [52]. In total, 2,875 patients diagnosed between 
2001  and  2003  were  followed  up  for  prostate  cancer 
mortality through January 2008. Overall, 626 (21%) of the 
patients died during follow-up and of those 440 (15%) 
had prostate cancer classified as their underlying cause of 
death.  No  association  between  any  of  the  explored 
variants  and  prostate  cancer  mortality  was  observed, 
either in exploring individual variants or in assessing the 
cumulative effect of all variants.
Additional studies in large populations are needed to 
comprehensively explore possible associations, although 
current evidence suggests that established risk variants 
are not risk factors for prostate cancer outcome.
Future clinical use of genetic factors
Recent GWAS studies have been successful in identifying 
many  low-penetrant  susceptibility  alleles  for  prostate 
cancer, and it is anticipated that many more variants will 
be  detected  through  combined  analysis  across  existing 
studies, new generations of larger studies, and increasing 
size of replication studies. Individually, each risk variant 
has a modest effect on disease risk and they will clearly 
not be useful for individualized risk prediction. However, 
risk profiles based on a combination of risk variants lead 
to an appreciable increased risk of disease [35] and there 
is  potential  for  the  predictive  power  to  increase  con-
siderably  as  more  risk  variants  are  detected  [53].  This 
may have important implications for targeted prevention 
and  screening  programs  for  prostate  cancer  through 
identification of high-risk groups. 
Since  there  is  considerable  co-morbidity  associated 
with  curative  treatment  of  prostate  cancer  (surgery  or 
radiotherapy), there is clear clinical utility in detecting 
Wiklund Genome Medicine 2010, 2:45 
http://genomemedicine.com/content/2/7/45
Page 4 of 7genetic markers that can improve discrimination between 
those patients that will follow a benign course from those 
with tumors that carry a poor prognosis and for whom 
curative  therapy  is  indicated.  In  addition,  inherited 
genetic markers, in contrast to measurement of a tumor-
derived product, can be informative at an earlier stage 
when  the  disease  is  potentially  curable.  However,  it  is 
evident  that  hitherto  identified  prostate  cancer  risk 
variants  provide  little  or  no  discriminative  capacity 
between indolent and aggressive forms of prostate cancer. 
Large GWAS among affected men contrasting more and 
less  aggressive  cases,  and  exploring  association  with 
disease  progression  and  prostate  cancer  mortality,  are 
clearly  needed  to  detect  inherited  genetic  variants 
associated  with  aggressive  forms  of  prostate  cancer. 
Initial findings indicate that genetic variants predisposing 
to  more  aggressive  disease  exist  [50]  and  this  is  also 
supported by recent epidemiological studies proposing a 
genetic component in cancer prognosis [54,55]. 
The detection of inherited genetic markers capable of 
discriminating  between  indolent  and  fatal  forms  of 
prostate cancer holds promise to improve detection and 
clinical management of this disease in several ways. A 
genetic-based,  targeted  PSA  screening  strategy  may 
reduce both overdiagnosis and mortality by identifying 
those men at risk for fatal prostate cancer at a curable 
stage. In addition, extended tools to guide clinicians in 
treatment  decisions  are  critical  to  improve  disease 
prognosis and decrease treatment-induced morbidity.
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